Related Experiment Video

Updated: Jun 18, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Issues of imatinib and pregnancy outcome

Jane Apperley1

  • 1Imperial College, Hammersmith Campus, London, England W12 0NN. j.apperley@imperial.ac.uk

Journal of the National Comprehensive Cancer Network : JNCCN
|November 26, 2009
PubMed

Insights

Tyrosine kinase inhibitors improve chronic myelogenous leukemia survival, but fertility and pregnancy concerns persist. Imatinib is generally safe for male fertility, but carries risks for fetal development in women.

Area of Science:

  • Hematology
  • Oncology
  • Reproductive Medicine

Background:

  • Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myelogenous leukemia (CML) treatment, leading to improved survival and normal life expectancies.
  • Increased survival necessitates addressing quality of life issues, including fertility and procreation for CML patients.
  • Lifelong TKI therapy may impact reproductive health, necessitating careful consideration during treatment planning.

Purpose of the Study:

  • To evaluate the impact of imatinib on fertility and pregnancy outcomes in chronic myelogenous leukemia patients.
  • To provide guidance on managing fertility and pregnancy in CML patients undergoing TKI therapy.

Main Methods:

  • Review of existing animal and human data regarding imatinib's effects on fertility and embryogenesis.
  • Analysis of pregnancy outcomes in women exposed to imatinib during gestation.
  • Consideration of alternative management strategies for pregnancy in CML.

Main Results:

  • Animal studies suggest imatinib does not impair fertility in adult males or females.
  • Limited human data indicate children born to men on imatinib appear healthy; discontinuation is not advised.
  • Pregnancy exposure in women shows concerning rates of congenital malformations, advising against imatinib use during organogenesis.
  • Alternative strategies like leukapheresis and interferon-alpha are considered for managing CML during pregnancy.

Conclusions:

  • Imatinib's safety profile for male fertility is favorable, but risks to fetal development in women require caution.
  • Careful management and alternative strategies are crucial for CML patients desiring procreation.
  • Further research is needed, especially in pediatric and adolescent populations, to fully understand TKI effects on fertility and pregnancy.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genomic Imprinting and Inheritance02:30

Genomic Imprinting and Inheritance

Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...